TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham upgraded the rating on the stock to a Buy and gave it a $148.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors that suggest strong future performance for TransMedics Group. The company’s recent data indicates that their U.S. sales are likely to surpass market expectations in the third quarter of 2025, as shown by the latest SRTR data. This positive outlook is further supported by the company’s ongoing heart and lung clinical trials, which are anticipated to drive growth in 2026.
Moreover, TransMedics Group is expanding internationally, which is expected to contribute to its growth trajectory. The company is also experiencing rapid margin improvements, leading to a potential increase in earnings per share. While competition poses a risk, Matson believes that TransMedics holds a significant advantage in a market that remains largely untapped.
Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Hologic. According to TipRanks, Matson has an average return of -2.3% and a 41.48% success rate on recommended stocks.
In another report released on October 21, TD Cowen also reiterated a Buy rating on the stock with a $170.00 price target.